AMICUS THERAPEUTICS, INC. — Director's Dealing 2018

Sep 11, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-09-07

Reporting Person: Bleil Lynn Dorsey (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-07	Common Stock	A	9600	$0.00	Acquired	9600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-07	Stock Option (right to buy)	$12.50	A	14605	Acquired	2028-09-07	Common Stock (14605)	Direct

Footnotes

F1: These restricted stock units (RSUs) vest in a series of installments. The first installment, which consists of 25% of the total aggregate number of RSUs vest on September 7, 2019 and the remaining RSUs vest in a series of thirty-five monthly installments beginning on October 1, 2019. Each restricted stock unit represents a right to receive one share of Amicus Therapeutics, Inc. common stock.

F2: These stock options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of stock options vest and become exercisable on September 7, 2019 and the remaining stock options vest and become exercisable in a series of thirty-five monthly installments beginning on October 1, 2019.